Dominant negative (ΔN) p63α induces drug resistance in hepatocellular carcinoma by interference with apoptosis signaling pathways

Biochemical and Biophysical Research Communications

Volumn 396, Issue 2, 2010, Pages 335-341

  Mundt, Heiko M ^a   Stremmel, Wolfgang ^a   Melino, Gerry ^b,c   Krammer, Peter H ^d   Schilling, Tobias ^a   Müller, Martina ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Apoptosis; Chemosensitivity; Dominant negative p63; Hepatocellular carcinoma; p53 family

Indexed keywords

BIM PROTEIN; DEATH RECEPTOR; DOXORUBICIN; FAS ANTIGEN; MITOCHONDRIAL PROTEIN; MITOXANTRONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN NOXA; PROTEIN P53; PROTEIN P63; PUMA PROTEIN; TRANSCRIPTION FACTOR; ANTINEOPLASTIC AGENT; TP63 PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TUMOR SUPPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; GENE ACTIVATION; GENE TARGETING; GENETIC REGULATION; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER CELL CARCINOMA; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; SIGNAL TRANSDUCTION; TRANSACTIVATION; TRANSCRIPTION INITIATION; DRUG RESISTANCE; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; LIVER TUMOR; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIVER NEOPLASMS; SEQUENCE DELETION; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 77952743819     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.04.093     Document Type: Article

References (34)

1. Yang A., Kaghad M., Wang Y., et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2 (1998) 305-316
2. Yang A., Schweitzer R., Sun D., et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398 (1999) 714-718
3. Mills A.A., Zheng B., Wang X.J., et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 398 (1999) 708-713
4. Levine A.J., and Oren M. The first 30 years of p53: growing ever more complex. Nat. Rev. Cancer 9 (2009) 749-758
5. Müller M., Schleithoff E.S., Stremmel W., et al. One, two, three - p53, p63, p73 and chemosensitivity. Drug Resist. Updat. 9 (2006) 288-306
6. Candi E., Dinsdale D., Rufini A., et al. TAp63 and DeltaNp63 in cancer and epidermal development. Cell Cycle 6 (2007) 274-285
7. Flores E.R., Sengupta S., Miller J.B., et al. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7 (2005) 363-373
8. Guo X., Keyes W.M., Papazoglu C., et al. TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat. Cell Biol. 11 (2009) 1451-1457
9. Patturajan M., Nomoto S., Sommer M., et al. DeltaNp63 induces beta-catenin nuclear accumulation and signaling. Cancer Cell 1 (2002) 369-379
10. Gressner O., Schilling T., Lorenz K., et al. TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO J. 24 (2005) 2458-2471
11. Suh E.K., Yang A., Kettenbach A., et al. p63 protects the female germ line during meiotic arrest. Nature 444 (2006) 624-628
12. Lee H.O., Lee J.H., Choi E., et al. A dominant negative form of p63 inhibits apoptosis in a p53-independent manner. Biochem. Biophys. Res. Commun. 344 (2006) 166-172
13. Adorno M., Cordenonsi M., Montagner M., et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137 (2009) 87-98
14. Koga F., Kawakami S., Fujii Y., et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin. Cancer Res. 9 (2003) 5501-5507
15. Morita M., Uramoto H., Nakata S., et al. Expression of deltaNp63 in squamous cell carcinoma of the esophagus. Anticancer Res. 25 (2005) 3533-3539
16. Crum C.P., and McKeon F.D. p63 in epithelial survival, germ cell surveillance, and neoplasia. Annu. Rev. Pathol. 5 (2010) 349-371
17. Seitz S.J., Schleithoff E.S., Koch A., et al. Chemotherapy-induced apoptosis in hepatocellular carcinoma involves the p53 family and is mediated via the extrinsic and the intrinsic pathway. Int. J. Cancer 126 (2010) 2049-2066
18. Müller M., Schilling T., Sayan A.E., et al. TAp73/DeltaNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12 (2005) 1564-1577
19. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
20. Nicoletti I., Migliorati G., Paggliacci M.C., et al. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 271-279
21. Galluzzi L., Aaronson S.A., Abrams J., et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ. 16 (2009) 1093-1107
22. Müller M., Strand S., Hug H., et al. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. J. Clin. Invest. 99 (1997) 403-413
23. Müller M., Wilder S., Bannasch D., et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med. 188 (1998) 2033-2045
24. Schilling T., Schleithoff E.S., Kairat A., et al. Active transcription of the human FAS/CD95/TNFRSF6 gene involves the p53 family. Biochem. Biophys. Res. Commun. 387 (2009) 399-404
25. Ihrie R.A., Marques M.R., Nguyen B.T., et al. Perp is a p63-regulated gene essential for epithelial integrity. Cell 120 (2005) 843-856
26. Westfall M.D., Joyner A.S., Barbieri C.E., et al. Ultraviolet radiation induces phosphorylation and ubiquitin-mediated degradation of DeltaNp63alpha. Cell Cycle 4 (2005) 710-716
27. Chatterjee A., Upadhyay S., Chang X., et al. U-box-type ubiquitin E4 ligase, UFD2a attenuates cisplatin mediated degradation of DeltaNp63alpha. Cell Cycle 7 (2008) 1231-1237
28. Osada M., Park H.L., Nagakawa Y., et al. Differential recognition of response elements determines target gene specificity for p53 and p63. Mol. Cell. Biol. 25 (2005) 6077-6089
29. Kaghad M., Bonnet H., Yang A., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90 (1997) 809-819
30. Ratovitski E.A., Patturajan M., Hibi K., et al. p53 associates with and targets DeltaNp63 into a protein degradation pathway. Proc. Natl. Acad. Sci. USA 98 (2001) 1817-1822
31. Flores E.R., Tsai K.Y., Crowley D., et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416 (2002) 560-564
32. Barbieri C.E., Perez C.A., Johnson K.N., et al. IGFBP-3 is a direct target of transcriptional regulation by DeltaNp63alpha in squamous epithelium. Cancer Res. 65 (2005) 2314-2320
33. Dohn M., Zhang S., and Chen X. p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 20 (2001) 3193-3205
34. Wu G., Nomoto S., Hoque M.O., et al. DeltaNp63alpha and TAp63alpha regulate transcription of genes with distinct biological functions in cancer and development. Cancer Res. 63 (2003) 2351-2357